Nasal sprays could be the future of treatment for Parkinson’s disease
Scientists at the University of York have made significant progress in the development of a nasal spray treatment for patients with Parkinson’s disease.
Researchers have developed a new gel that can adhere to tissue inside the nose alongside the drug levodopa, helping deliver treatment directly to the brain.
Levodopa is converted to dopamine in the brain, which makes-up for the deficit of dopamine-producing cells in Parkinson’s patients, and helps treat the symptoms of the disease. Over extended periods of time, however, levodopa becomes less effective, and increased doses are needed.
Increased dosage
Professor David Smith, from the University of York’s Department of Chemistry, said: “The current drug used for Parkinson’s Disease is effective to a point, but after a long period of use the body starts to breakdown the drug before it gets to the brain where it is most needed.
“This means increased dosage is necessary, and in later stages, sometimes, instead of tablets, the drug has to be injected. Investigations into nasal sprays have long been of interest as a more effective delivery because of its direct route to the brain via the nerves that service the nose, but the challenge here is to find a way of making it adhere to the nasal tissue long enough to release a good dosage of the drug.”
The researchers created a gel, loaded with levodopa, that could flow into the nose as a liquid and then rapidly change to a thin layer of gel inside the nose. The method was tested in animal models by a team at King’s College London, where levodopa was successfully released from the gel into the blood and directly to the brain.
Better uptake
Professor Smith said: “The results indicated that the gel gave the drug better adhesion inside the nose, which allowed for better levels of uptake into both the blood and brain.”
The team are now working to incorporate these materials in nasal spray devices to progress to clinical trials in humans. The approach may also be relevant to other neurodegenerative diseases such as Alzheimer’s.
Khuloud Al-Jamal, Professor of Drug Delivery and Nanomedicine from King’s College London, said: “Not only did the gel perform better than a simple solution, but the brain uptake was better than that achieved using intravenous injection of the drug. This suggests that nasal delivery of Parkinson’s drugs using this type of gel may have clinical relevance.”
Original Article: Step-closer to nasal spray drug delivery for Parkinson’s disease
More from: University of York | King’s College London
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Nasal spray drug delivery
- Can nasal Neosporin fight COVID? Surprising new research suggests it works
A potential treatment for COVID-19 may have been hiding in our medicine cabinets, a new study in PNAS has found ...
- National Prescription Drug Take Back Day: Dane County sites accept unwanted medicines
Unused medicine should never be flushed down the toilet or poured down the drain, the group says, because water reclamation facilities are not designed to remove all of them.
- Berry Global invests to increase production capacity
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites.
- Engineers muffle invading pathogens with a 'molecular mask'
Vaccines remain the gold standard of protection against dangerous pathogens, but take considerable time and vast resources to develop. Rapidly mutating viruses such as SARS-CoV-2 can blunt their ...
- Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal ; Study met primary efficacy endpoint of improvement in nasa ...
Go deeper with Google Headlines on:
Nasal spray drug delivery
[google_news title=”” keyword=”nasal spray drug delivery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Parkinson’s Disease
- Parkinson’s UK invests £2.1 million in Neumora Therapeutics for preclinical testing of new Parkinson’s drug
Parkinson’s UK is investing £2.1million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation and protect brain ...
- ‘Everyone can help fight Parkinson’s disease’
Research, clinical trials and a care network across the country support patients and help deliver important new knowledge ...
- Recognizing symptoms of Parkinson's disease
April is Parkinson's disease Awareness Month, which make this a good time to learn about the symptoms of Parkinson's disease. An estimated 1 million people in the U.S. and more than 10 million people ...
- Predicting Parkinson’s: Can Retinal Thickness Unlock Future Cognitive Decline?
A research collaboration between the University of the Basque Country (UPV/EHU) and Biobizkaia suggests employing a readily available, straightforward, and non-invasive method to track ...
- Decoding Parkinson’s disease: New genetic variant offers hope for future treatments
Researchers have discovered a new genetic variant, RAB32 Ser71Arg, linked to Parkinson's disease across several countries. This variant interacts with proteins affecting dopamine levels and cell ...
Go deeper with Google Headlines on:
Parkinson’s Disease
[google_news title=”” keyword=”Parkinson’s Disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]